Title Credit Type Event date Cost
The Staying Power of Immunotherapies: Approaching Melanoma Care from an Inclusive Perspective
    • 1.75 ACPE Pharmacy
    • 1.75 AMA PRA Category 1 Credit
    • 1.75 ANCC
    • 1.75 Participation
Enduring $0.00
Virtual Symposium: CGM - Going Beyond HbA1c to Optimize and Individualize T2D Management
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit
    • 0.50 ANCC
    • 0.50 Participation
Enduring $0.00
BRAINWeek 2022 Digital All Access
    • 26.00 ACCME (MD/DO Only)
    • 26.00 AANP
    • 26.00 AAFP
    • 26.00 APA
    • 26.00 ACCME (All Other)
    • 26.00 ACPE Pharmacy
    • 26.00 ANCC
Enduring $499.00
Virtual Symposium - Assessing the Role of TAVR Across the Risk Continuum: Emerging Evidence, Evolving Guidance, and Expert Perspectives
    • 1.00 CDE
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit
    • 1.00 ANCC
    • 1.00 Participation
Enduring $0.00
Webcast: Challenging Cases in Patients with Iron Deficiency and Heart Failure
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit
    • 0.50 ANCC
    • 0.50 Participation
Enduring $0.00
Webcast: Advances in Screening, Diagnosis, and Treatment of Iron Deficiency in Heart Failure Patients
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit
    • 1.00 ANCC
    • 1.00 Participation
Enduring $0.00
Clinical Brief: Should Diabetes Management be More Adipose-centric?
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit
    • 0.50 ANCC
    • 0.50 Participation
Enduring $0.00
Digital Pathway: Challenges and Advances in the Diagnosis and Management of Immune Thrombocytopenic Purpura
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit
    • 1.00 ANCC
    • 1.00 Participation
Enduring $0.00
Clinical Brief: The Disproportionate Burden of ATTR-CM In African Americans
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit
    • 0.50 ANCC
    • 0.50 Participation
Enduring $0.00
Digital Pathway - Changing The Treatment Paradigm for LDL-C Lowering Post-MI: The Case for Early, ‘High-Intensity Lipid Lowering Therapy’ to Improve...
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit
    • 1.50 ANCC
    • 1.50 Participation
Enduring $0.00
Digital Pathway - Bridging the Frontiers of Care in Patients with T2D and CKD: Interpreting the Data with Novel MR Antagonists to Improve Cardiorenal...
    • 1.00 CDE
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit
    • 1.00 ANCC
    • 1.00 Participation
Enduring $0.00

Pages